This handout is for acute renovascular flash pulmonary edema (pickering syndrome). Your care team identified this based on: recurrent flash pulmonary edema episodes + resistant htn despite ≥3 antihypertensives (incl diuretic) — pickering syndrome screen.
Other reasons your team may use this plan: aki (cr rise >30%) within 1-2 wk of starting acei/arb — pathognomonic for bilateral ras or unilateral ras with single functioning kidney; asymmetric kidney size on prior imaging (>1.5 cm difference) or atrophic kidney — ras suspicion; acute dyspnea + orthopnea + severe htn + atherosclerotic vascular disease (cad, pad, aaa) — atherosclerotic ras phenotype.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| nitroglycerin | 5-10 µg/min IV, titrate by 5 µg/min q5min up to 200 µg/min | IV | continuous | ACC/AHA 2025 first-line — preload + afterload reduction; rapid onset; AVOID if SBP <90 / RV infarct / PDE5 within 24-48h |
| furosemide | 40-80 mg IV bolus (or 1-2× home daily dose if chronic HF) per DOSE | IV | q12h or continuous infusion 5-20 mg/h | DOSE trial PMID 21366472 — high-dose IV; reassess UOP at 2h; maintenance for chronic Pickering with diuretic-responsive volume |
| amlodipine | Amlodipine 5-10 mg PO daily | PO | daily | CCB safe in any RAS (no kidney perfusion risk like ACEi/ARB); ACC/AHA 2025 first-line for Pickering chronic management |
| nicardipine | 5 mg/h IV titrate by 2.5 mg/h q5-15 min | IV | continuous | Add when NTG alone insufficient; safe with HF (does not worsen LV function); CCB-class consistent with chronic plan |
| labetalol | 20 mg IV q10 min OR 200 mg PO BID maintenance | IV or PO | bolus or BID | Useful adjunct; cautious use in acute decompensated HF |
| minoxidil | 2.5-5 mg PO daily, titrate to 10-40 mg daily | PO | daily-BID | Reserved for resistant HTN; ALWAYS combine with BB + loop diuretic (reflex tachycardia + Na/H2O retention); useful bridge to revasc |
| NIPPV (CPAP 8-10 cmH2O or BiPAP 12/5) | CPAP 8-10 cmH2O OR BiPAP IPAP 12 / EPAP 5; titrate to SpO2 >92 | mask | continuous | 3CPO trial PMID 18768944 — NIPPV reduces intubation rate vs standard O2 in cardiogenic pulm edema |
| Renal artery angioplasty + stenting | Per IR / vascular surgery; stent in atherosclerotic; angioplasty alone often durable in FMD | endovascular | definitive procedure | CORAL PMID 24245566 — null overall but flash-pulm-edema subgroup analyses suggest benefit; AHA 2014 Scientific Statement supports revasc in flash edema phenotype + resistant HTN; FMD has high success with angioplasty alone |
| AVOID ACE inhibitors / ARBs in BILATERAL RAS | AVOID | N/A | N/A | Pathophysiology: efferent arteriole dilation → loss of GFR-maintaining pressure → precipitous AKI; ACEi/ARB challenge often the diagnostic reveal; safe in unilateral RAS with normal contralateral kidney + close Cr monitoring |
| AVOID nitroprusside if eGFR <30 | AVOID | N/A | N/A | Cyanide accumulation risk; CKD common in chronic Pickering due to chronic ischemic nephropathy |
| AVOID isolated diuretic without vasodilator in acute episode | AVOID | N/A | N/A | Diuretic alone in HTN-driven flash edema = incomplete unloading; preload + afterload reduction with NTG is FIRST move (ACC/AHA 2025) |
Plan: Pickering syndrome — acute flash edema bundle (NTG/loop/NIPPV) + chronic CCB-based regimen + AVOID ACEi/ARB in bilateral RAS + revascularization decision
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Outpatient: revascularization decision (vascular surgery + IR + nephrology multidisciplinary); long-term BP control with CCB-based regimen + diuretic ± minoxidil + ARB cautious trial post-revasc if anatomy permits; statin + ASA for atherosclerotic RAS (secondary prevention); FMD: lifelong surveillance for vascular FMD elsewhere (cervicocephalic, mesenteric); 1-week follow-up; cardiac rehab if first HF episode
Guideline: 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493) + ESC 2021 HF Guideline (PMID 34447992) + AHA 2014 RAS Scientific Statement (PMID 24685930) + CORAL trial (PMID 24245566)